Tien Dong
Gastroenterology · Santa Monica, CANPI 1730443177
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,720 of the $109,210 with a category attached, or 91.3%. Mallinckrodt Hospital Products Inc. accounts for 98.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $79,150 and has fallen 63.1% since, to $29,230 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $1560.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$108K
- ERBE USA Inc$400
- Kerecis Limited$243
- GSK$207
- Evoke Pharma, Inc.$162
- Madrigal Pharmaceuticals$148
- plus $53 from 2 others
Across 3 payments — averaging $5405.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Bioscience Inc.$16K
What the payments were for
- Speaking & faculty fees$99,72091%
- Travel & lodging$6,9036%
- Food & beverage$2,5872%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 60 | $107,996 |
| ERBE USA Inc | 2 | $400 |
| Kerecis Limited | 2 | $243 |
| GSK | 2 | $207 |
| Evoke Pharma, Inc. | 1 | $162 |
| Madrigal Pharmaceuticals | 1 | $148 |
| AbbVie | 1 | $28 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$107,501
- ERBE$400
- Kerecis Omega3 SurgiClose$378
- GIMOTI$162
- RESMETIROM$148
- Kerecis Omega3 GraftGuide$126
- Kerecis Omega3 Marigen$126
- Kerecis Omega3 Wound$117
How this compares
$109,210 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 16 | $49,427 |
| OzempicSemaglutide | 27 | $24,270 |
| Ursodiol | 29 | $2,427 |
| Tenofovir Disoproxil Fumarate | 16 | $2,062 |
| Spironolactone | 16 | $334 |
| Furosemide | 27 | $216 |
| Carvedilol | 18 | $84 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Santa Monica
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.